Category Archives: Medical Treatments
Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, NiCord®, in development as a novel graft modality for bone marrow transplantation in patients with high risk haematological malignancies (blood cancers) such as leukaemia and lymphoma.
NiCord® is cryopreserved (frozen) umbilical cord blood stem and progenitor cells, that were expanded (population increased) ex-vivo (outside of the body). NiCord® is derived from a single umbilical cord blood unit which has been expanded in culture and enriched with stem and progenitor cells using Gamida Cell’s proprietary NAM technology, and is in development as an investigational therapeutic treatment for blood cancers such as leukemia and lymphoma and for non-malignant haematological diseases.
NiCord® was originally transplanted as a “fresh” product that had to be infused into the patient within a limited number of hours from the moment the product was released from the manufacturing site. This timetable restricted the window for transplantation for the patient and limited the location of manufacturing sites to the vicinity of participating medical centers;it also increased the cost of shipping and logistical support required from manufacturing through delivery.
The first person was successfully transplanted with cryopreserved (frozen) NiCord in the company’s ongoing Phase I/II clinical study for blood cancer patients in January 2015.
Most Brain Cancers are treated with Radiation Therapy, but the cancer cells can repair themselves in order to live on.
Researchers at Sidney’s Kimmel Cancer Center recently tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumours to mend themselves.
According to the research, published in the Journal of Neuro-Oncology, results of the study are such that a more comprehensive, phase 2 clinical trial should be conducted to test the combination therapy for aggressive, recurrent brain cancer.
“We saw synergy between radiotherapy and the agent, panobinostat. Our findings suggest panobinostat makes radiotherapy much more effective,” says the study’s senior author, Yaacov R. Lawrence, M.D., of the Department of Radiation Oncology at Thomas Jefferson University’s Sidney Kimmel Medical College.
All 12 patients tested in the study had high-grade gliomas that had recurred after initial radiotherapy. Eight patients had recurrent glioblastoma, and four had recurrent anaplastic astrocytoma.
Acute Lymphoblastic Leukaemia is the most common form of childhood cancer, but thanks to research, up to nine in 10 children diagnosed with ALL will now achieve a long-term cure. Unfortunately, in those whose disease relapses, the prognosis is not that good and fewer than 6 in 10 children survive longer than 5 years.
Researchers at Newcastle University have recently completed the largest study of its kind, and thanks to their findings, doctors will now be able to analyse the genetic profile of cancer cells to personalise treatment and improve survival rates.
The Newcastle study, Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia, published in the prestigious journal Blood, analysed leukaemia cells from 427 children treated for relapsed Acute Lymphoblastic Leukaemia between 2003 and 2013, using a variety of genetic tests including fluorescence in situ hybridisation (FISH), where glowing tags are bound to sequences of DNA within the cancer cells, allowing scientists to view specific genetic changes under a microscope.
Genetic faults within developing white blood cells kick-start and drive leukaemia growth. The types and combinations of genetic errors are known to influence whether a child is likely to respond well to initial treatment, which in turn affects whether they have a good or poor chance of survival.
This page is being updated as we can so please come back frequently to check new information
Childhood Cancer is very different to Adult Cancer and is therefore not treated the same as Adult Cancer. Paediatric Cancer Centres generally offer extra support services for children and their families, such as child life specialists, nutritionists, physical and occupational therapists, social workers, counsellors. Special activities and programs to help your child and family cope may also be available. There are, however, times when a teenager with cancer may need to be treated at an Adult Cancer Centre.
All Children with Cancer should be treated at a specialised cancer centre. Doctors at these centres have extensive experience in treating children with cancer and have access to the latest research. In many cases, a team of doctors works with a child and the family to provide care; this is called a multidisciplinary team.
This section will eventually contain all available information about all the main cancer treatments for Childhood Cancer, including surgery, radiotherapy, chemotherapy, and bone marrow and stem cell transplants.
We will also provide information about complementary and alternative therapies.
The treatment of childhood cancer depends on several factors, including the type and stage of cancer, possible side effects, the family’s preferences, and the child’s overall health. Your child’s care plan may also include treatment for symptoms and side effects, an important part of cancer care.
Take time to learn about all of your child’s treatment options and be sure to ask questions about things that are unclear.
Also, talk about the goals of each treatment with your doctor and what to expect while receiving the treatment.